These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

147 related items for PubMed ID: 7781142

  • 1. Comparative resistance of idarubicin, doxorubicin and their C-13 alcohol metabolites in human MDR1 transfected NIH-3T3 cells.
    Kuffel MJ, Ames MM.
    Cancer Chemother Pharmacol; 1995; 36(3):223-6. PubMed ID: 7781142
    [Abstract] [Full Text] [Related]

  • 2. Cellular pharmacology of idarubicinol in multidrug-resistant LoVo cell lines.
    Toffoli G, Corona G, Simone F, Gigante M, De Angeli S, Boiocchi M.
    Int J Cancer; 1996 Jul 03; 67(1):129-37. PubMed ID: 8690513
    [Abstract] [Full Text] [Related]

  • 3. Differential effects of P-glycoprotein inhibitors on NIH3T3 cells transfected with wild-type (G185) or mutant (V185) multidrug transporters.
    Cardarelli CO, Aksentijevich I, Pastan I, Gottesman MM.
    Cancer Res; 1995 Mar 01; 55(5):1086-91. PubMed ID: 7866993
    [Abstract] [Full Text] [Related]

  • 4. Anthracyclines and their C-13 alcohol metabolites: growth inhibition and DNA damage following incubation with human tumor cells in culture.
    Kuffel MJ, Reid JM, Ames MM.
    Cancer Chemother Pharmacol; 1992 Mar 01; 30(1):51-7. PubMed ID: 1586980
    [Abstract] [Full Text] [Related]

  • 5. Cellular uptake and antiproliferative effects of therapeutic concentrations of idarubicin or daunorubicin and their alcohol metabolites, with or without cyclosporin A, in MDR1+ human leukemic cells.
    Chiodini B, Bassan R, Barbui T.
    Leuk Lymphoma; 1999 May 01; 33(5-6):485-97. PubMed ID: 10342576
    [Abstract] [Full Text] [Related]

  • 6. Medroxyprogesterone-acetate reverses the MDR phenotype of the CG5-doxorubicin resistant human breast cancer cell line.
    Zibera C, Gibelli N, Maestri L, Della Cuna GR.
    Anticancer Res; 1995 May 01; 15(3):745-9. PubMed ID: 7645952
    [Abstract] [Full Text] [Related]

  • 7. Restoring uptake and retention of daunorubicin and idarubicin in P170-related multidrug resistance cells by low concentration D-verapamil, cyclosporin-A and SDZ PSC 833.
    Michieli M, Damiani D, Michelutti A, Candoni A, Masolini P, Scaggiante B, Quadrifoglio F, Baccarani M.
    Haematologica; 1994 May 01; 79(6):500-7. PubMed ID: 7896208
    [Abstract] [Full Text] [Related]

  • 8. Idarubicin overcomes P-glycoprotein-related multidrug resistance: comparison with doxorubicin and daunorubicin in human multiple myeloma cell lines.
    Roovers DJ, van Vliet M, Bloem AC, Lokhorst HM.
    Leuk Res; 1999 Jun 01; 23(6):539-48. PubMed ID: 10374847
    [Abstract] [Full Text] [Related]

  • 9. Relation among the resistance factor, kinetics of uptake, and kinetics of the P-glycoprotein-mediated efflux of doxorubicin, daunorubicin, 8-(S)-fluoroidarubicin, and idarubicin in multidrug-resistant K562 cells.
    Mankhetkorn S, Dubru F, Hesschenbrouck J, Fiallo M, Garnier-Suillerot A.
    Mol Pharmacol; 1996 Mar 01; 49(3):532-9. PubMed ID: 8643093
    [Abstract] [Full Text] [Related]

  • 10. Induction of MDR1 gene expression by anthracycline analogues in a human drug resistant leukaemia cell line.
    Hu XF, Slater A, Rischin D, Kantharidis P, Parkin JD, Zalcberg J.
    Br J Cancer; 1999 Feb 01; 79(5-6):831-7. PubMed ID: 10070877
    [Abstract] [Full Text] [Related]

  • 11. Comparison of mechanisms responsible for resistance to idarubicin and daunorubicin in multidrug resistant LoVo cell lines.
    Toffoli G, Simone F, Gigante M, Boiocchi M.
    Biochem Pharmacol; 1994 Nov 16; 48(10):1871-81. PubMed ID: 7986198
    [Abstract] [Full Text] [Related]

  • 12. Modeling the metabolism of idarubicin to idarubicinol in rat heart: effect of rutin and phenobarbital.
    Kang W, Weiss M.
    Drug Metab Dispos; 2003 Apr 16; 31(4):462-8. PubMed ID: 12642473
    [Abstract] [Full Text] [Related]

  • 13. Lentivirus-mediated RNA interference reversing the drug-resistance in MDR1 single-factor resistant cell line K562/MDR1.
    Ye X, Liu T, Gong Y, Zheng B, Meng W, Leng Y.
    Leuk Res; 2009 Aug 16; 33(8):1114-9. PubMed ID: 19036441
    [Abstract] [Full Text] [Related]

  • 14. The potential of N-[2-(dimethylamino)ethyl]acridine-4-carboxamide to circumvent three multidrug-resistance phenotypes in vitro.
    Davey RA, Su GM, Hargrave RM, Harvie RM, Baguley BC, Davey MW.
    Cancer Chemother Pharmacol; 1997 Aug 16; 39(5):424-30. PubMed ID: 9054956
    [Abstract] [Full Text] [Related]

  • 15. Quantitation of doxorubicin uptake, efflux, and modulation of multidrug resistance (MDR) in MDR human cancer cells.
    Shen F, Chu S, Bence AK, Bailey B, Xue X, Erickson PA, Montrose MH, Beck WT, Erickson LC.
    J Pharmacol Exp Ther; 2008 Jan 16; 324(1):95-102. PubMed ID: 17947497
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. New silicon compounds as resistance modifiers against multidrug-resistant cancer cells.
    Molnar J, Mucsi I, Nacsa J, Hevér A, Gyémánt N, Ugocsai K, Hegyes P, Kiessig S, Gaal D, Lage H, Varga A.
    Anticancer Res; 2004 Jan 16; 24(2B):865-71. PubMed ID: 15161039
    [Abstract] [Full Text] [Related]

  • 19. Transduction of NIH 3T3 cells with a retrovirus carrying both human MDR1 and glutathione S-transferase pi produces broad-range multidrug resistance.
    Doroshow JH, Metz MZ, Matsumoto L, Winters KA, Sakai M, Muramatsu M, Kane SE.
    Cancer Res; 1995 Sep 15; 55(18):4073-8. PubMed ID: 7664283
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.